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This paper examines the role of therapeutic alliance in predicting outcomes in a Randomised 
Controlled Trial of Motivational Interviewing and Cognitive Behavioural Therapy (MICBT) 
for problematic cannabis use in recent onset psychosis.  
Methods 
All clients were participating in a three arm pragmatic rater-blind randomised controlled trial 
of brief MICBT plus standard care compared with longer term MICBT plus standard care and 
standard care alone. Participants completed measures to assess clinical symptoms, global 
functioning and substance misuse at baseline, 4.5 months, 9 months and 18 months.  Clients 
and therapists completed the Working Alliance Inventory approximately one month into 
therapy. Client alliance data was available for 35 participants randomised to therapy and 
therapist alliance data was available for 52 participants randomised to therapy.  
Results 
At baseline, poorer client-rated alliance was associated with more negative symptoms, poorer 
insight and greater cannabis use, whereas poorer therapist-rated alliance was only associated 
with amount of cannabis used per cannabis using day. Alliance ratings were also positively 
associated with amount of therapy: client-rated alliance was higher in the longer compared to 
the briefer therapy;  therapist-rated alliance was associated with greater number of sessions 
attended (controlling for type of therapy) and therapy completion. In predicting outcome, 
client-rated alliance predicted total symptom scores and global functioning scores at follow-





Findings demonstrate that individuals with psychosis and substance misuse who form better 
alliances with their therapists gain greater benefits from therapy, at least in terms of 
improvements in global functioning.  
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Poor alliance was associated with negative symptoms, poor insight and more cannabis use 
Alliance was better in longer compared to shorter-term therapy 











Cannabis use is common in young people experiencing early psychosis and is associated with 
worse outcomes  [1, 2]. The early stages of psychosis are critical for determining long-term 
outcomes and consequently research has focused on trialling psychological therapies to 
reduce cannabis use during this period. Studies have either evaluated Motivational 
Interviewing (MI)  or a combination of MI and Cognitive Behavioural Therapy (MICBT) [3], 
but there is  limited evidence of improvements in cannabis or clinical outcomes.  It has been 
suggested that due to the complexity of dual diagnosis, longer, more intensive treatments are 
needed  [4]. However, in a recent trial involving a long-term intervention of MICBT (24 
sessions delivered over 9 months) participants only attended a median of 50% of sessions and 
across both the long-term intervention and a briefer comparison therapy 20% of participants 
attended less than 2 sessions [5].   
Engagement difficulties are common in psychosis and can be even more problematic in the 
context of co-occurring substance misuse [3].  The emotional and collaborative relationship 
between clients and therapists, commonly referred to as ‘therapeutic alliance’ is an important 
predictor psychotherapy outcomes [6]. A positive therapeutic alliance is associated with 
treatment engagement and retention in clients with substance misuse [7] and early psychosis 
[8]. Alliance has also been shown to predict treatment outcomes in both established [9, 10] 
and early psychosis [8, 11].  
Evidence suggests that different factors predict client versus therapist alliance, and that 
predictors of alliance vary according to the client group or therapy provided [12-16]. 
However, poorer functioning, more negative symptom profiles and poorer ‘insight’ defined in 
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terms of the degree to which clients agreement with an ‘illness model’ seem to be among the 
most consistent predictors.   
This paper examines the role of therapeutic alliance in predicting outcomes in a RCT of 
MICBT for problematic cannabis use in recent onset psychosis. The trial found that neither 
an extended nor a brief intervention conferred benefit over standard care in terms of 
reductions in frequency or amount of cannabis use, nor any of the symptom or functioning 
outcomes assessed [5]. In the present study, we first investigated whether any participant 
baseline characteristics predict therapeutic alliance. Secondly, we analysed the relationship 
between therapeutic alliance and treatment outcomes, including engagement in therapy 
sessions and drop out. In line with previous studies, we hypothesised that poorer client 
functioning, poorer insight, more negative symptoms and greater substance misuse would be 
related to worse alliance.  We also hypothesised that a stronger therapeutic alliance would 
predict session attendance, retention in therapy and outcomes for both symptoms and 
substance misuse.  As alliance is a predictor of outcome across therapeutic modalities and 
both treatments specifically focused on developing a strong therapeutic alliance with clients, 





Clients were participating in a three-arm pragmatic rater-blind RCT of brief MICBT 
compared with longer-term MICBT and standard care alone (Figure 1). Trial participants 
were recruited from Early Intervention Services and inclusion criteria were: aged 16-35; 
DSM-IV diagnosis for non-affective psychosis; DSM-IV diagnosis of cannabis dependence 
or abuse; cannabis use of at least one day per week in at least half the weeks in the past three 
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months; stable accommodation; English speaking; no history of organic factors implicated in 
the aetiology of psychotic symptoms; and informed consent.  Client alliance data was 
available for 35 of 75 participants randomised to therapy and therapist alliance data was 




2.2.1 Demographic information 
Demographic information and years of cannabis misuse were collected at baseline via self-
report.  Duration of psychosis was obtained from casenotes by trained assessors.   
 
2.2.2 Therapeutic alliance 
Therapeutic alliance was assessing by therapist and client versions of the 12-item Working 
Alliance Inventory (WAI[17] completed approximately one month into therapy [mean 
number of sessions for therapist WAI = 3.76 (1.32) and mean number of sessions for client 
WAI = 4.17 (1.47)]. Items are rated on a scale ranging from 1 (never) to 7 (always), with 
higher scores reflecting a stronger alliance. An overall index of alliance can be computed 
across the items (range 7 – 84).  
 
2.2.3 Assessment of outcomes 
All substance misuse, symptom and functioning outcome measures were completed at 
baseline, at 4.5 months (end of brief therapy), 9 months (end of longer-term therapy) and 18 
months after randomisation. 
 
2.2.4 Substance misuse 
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Substance misuse was assessed using the Time Line Follow Back assessment (TLFB[18]. 
The primary outcome for the trial was number of days abstinent from cannabis in the 
preceding 30 days, but additional outcomes were also recorded including number of days 
abstinent from all substances over the preceding 30 days, average amount of cannabis used 
per cannabis using day and changes in these measures from baseline to each follow-up. The 
TLFB has good reliability and validity in dual diagnosis populations [19].  
 
2.2.5 Symptoms and functioning 
The Positive and Negative Syndrome Scale (PANSS[20]) was used to assess  symptoms 
associated with psychosis. Each of the 30 items is rated on a scale, ranging from 1 (absence 
of psychopathology) to 7 (extreme psychopathology).  Functioning was assessed using the 
Global Assessment of Functioning Scale (GAF[21]  which can be used to derive total scores 
and subscale scores for symptoms and disability with higher scores representing better 
functioning (all ranges: 0-100). All research assistants were trained in rating the PANSS and 
GAF and high levels of inter-rater reliability with experienced raters were maintained 
throughout (all ICCs ≥ .85). 
 
2.2.6 Insight 
Insight was assessed using the Birchwood Insight Scale (BIS[22]). This eight-item self-report 
scale was designed to be sensitive to changes in levels of insight, and captures three 
dimensions of insight: perceived need for treatment, awareness of illness and re-labelling of 
symptoms as pathological. Higher scores indicate greater levels of insight (range 0-12). The 
BIS was completed at baseline. 
 
2.3 Procedure  
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Following ethical approval, written informed consent and screening, participants completed 
baseline assessment measures. Participants were then randomly allocated to one of the trial 
arms. Therapists were instructed to complete the WAIs after the client’s third therapy session 
(approximately one month into therapy) and also to provide WAIs to clients. Client WAIs 
were then placed in sealed stamped envelopes addressed to the trial manager.  The therapists 
and clients were assured that they would not be informed of each other’s ratings. Outcome 
assessments were completed with researchers blind to treatment allocation.  
 
2.4 Intervention 
The psychological therapy consisted of integrated MICBT and is described more fully in a 
paper reporting the main outcomes from the trial [5]. Participants in the brief intervention 
condition were offered up to 12 sessions of MICBT over 4.5 months and participants in the 
long-term intervention condition were offered up to 24 sessions over 9 months. The therapy 
was delivered by three therapists, who were trained in both CBT and MI and regularly 
supervised.   
 
2.5 Data analysis  
Associations between continuous parametric variables were assessed using Pearson’s 
correlations or Spearman Rho correlations (TLFB variables).  The association between 
alliance and therapy completion and alliance and treatment arm was assessed using 
independent t-tests. The role of alliance in predicting clinical outcomes was assessed using 
regression models controlling for baseline scores on each respective dependent variable. Data 
were analysed in accordance with intention to treat principles, using all available data.   
 
3. RESULTS  
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3.1. Sample characteristics  
A total of 110 participants were randomised. Thirty-five patients were allocated to standard 
care, 38 were allocated to brief therapy and 37 were allocated to longer-term therapy. 
Therapist WAI (T-WAI) data were available for 52 of the 75 therapy clients (69%) and client 
WAI (C-WAI) data were available for 35 of the 75 therapy clients (47%). Clients with 
missing WAIs had significantly lower therapist-rated alliance [t = 2.055 ( 50), p = .045; C-
WAI completed: Mean = 61.29 (8.71); C-WAI missing: Mean = 55.29 (11.94)] and a longer 
history of psychosis [t = -2.025 (73), p = .046; months of psychosis: C-WAI completed: 
Mean = 15.34 (11.53); C-WAI missing: Mean = 21.90 (15.85)]. Completion of T-WAIs were 
unrelated to any of the variables assessed at baseline and did not differ between the treatment 
arms. For dyads with missing data, non-completion was primarily due to non-attendance or 
therapists reporting that administering an alliance measure might have an adverse effect on 
therapy at that point in time.  Sample characteristics of clients with WAI data are presented in 
Table 1. As reported in the main paper of the trial, mean alliance scores were for both 
therapists and clients were comparable with alliance reported in previous psychosis trials.   
 
3.2.Therapist and client ratings of alliance in brief versus longer-term therapy                                                   
There were no significant differences between therapist-rated alliance in the brief compared 
to the longer-term therapy (t .555 (50), p = .581). However, clients rated the alliance as 
significantly better in the longer-term therapy compared to the brief therapy [t = 3.177 (33), p 
= .003; C-WAI longer-term therapy: Mean = 67.07 (8.16); C-WAI brief therapy: Mean = 
58.00 (8.25)], despite rating alliance at similar time points in both therapies and no 
statistically significant differences between the groups on any baseline measures. There was a 
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strong agreement between therapist and client scores (r = .60, p<.001); an effect that was 
evident across both therapies.   
 
3.3.Alliance and baseline measures (See Table 2) 
We found no significant associations between T-WAI and any of the measures collected at 
baseline, including demographic and illness-related variables, with the exception of average 
amount of cannabis per cannabis using day in preceding 30 days (grams), suggesting that 
therapists rated the alliance as poorer if clients reported using more cannabis. As predicted, 
there was a significant correlation between poorer C-WAI and more negative symptoms, 
poorer insight and greater cannabis use. However, there were no significant associations 
between C-WAI and client functioning or measures of all substance misuse.  
 
 
3.4. Alliance, session uptake and retention  
There was a significant positive correlation between number of sessions attended and T-WAI 
(r = .590, p = <.001) which was maintained when controlling for therapy type (partial 
correlation: r = .611, p <.001).  There was a positive trend of an association between C-WAI 
and number of sessions attended, but this finding did not reach significance (r = .306, p = 
.074). We also looked at whether alliance was related to therapy completion (assessed in 
terms of the presence of an end of therapy summary as per protocol). There were only 3 
completed C-WAIs for people who dropped out of therapy so it was not possible to compare 
groups of completers and non-completers on client-rated alliance.  There was, however, a 
significant group difference for completers and non-completers in terms of T-WAI, with 
those who completed therapy reporting higher levels of alliance [t = 4.007 (40), p <.001; 




3.5. Alliance and symptom outcomes  
We carried out a series of regression analyses to explore the influence of alliance on 
symptom outcomes controlling for baseline measures. T-WAI was not a statistically 
significant predictor of PANSS total scores or GAF total scores at any of the follow-up 
assessments (data not shown).  C-WAI statistically significantly predicted PANSS total 
scores at 9 months and 18 months, but associations between C-WAI and PANSS total scores 
only approached significance at the 4.5-month follow-up. C-WAI was a significant predictor 
of GAF total scores at all three follow-ups, suggesting that better alliance from the client 
perspective was associated with better functioning (see Table 3). These significant findings 
were replicated for the GAF symptoms subscale at all three follow-ups and GAF disability at 
the 4.5 and 18 month follow-ups (data not shown). 
 
3.6. Alliance and substance misuse outcome  
We looked at whether alliance was significantly correlated with changes in substance misuse 
at all three time points and found no statistically significant effects (See Table 4). 
 
4. DISCUSSION  
This study investigated baseline predictors of therapeutic alliance and the relationship 
between alliance and outcomes in clients with recent onset psychosis participating in a trial of 
MICBT for cannabis misuse. At baseline, we found that poorer client-rated alliance was 
associated with more negative symptoms, poorer insight and greater cannabis use, whereas 
poorer therapist-rated alliance was only associated with amount of cannabis used per 
cannabis using day. Client-rated alliance was also higher in the longer compared to the 
briefer therapy. We found that therapist-rated alliance was associated with both number of 
sessions attended (controlling for type of therapy) and therapy completion. However, client-
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rated alliance but not therapist-rated alliance predicted total symptom scores and global 
functioning scores at follow-up. Neither client nor therapist alliance predicted changes in 
substance misuse at any of the time points.  
Findings of associations between client-rated alliance and both negative symptoms [23, 24] 
and insight [10-12, 14, 16, 24-26] are consistent with a number of other studies. Is it possible 
that feeling positively about the relationship with the therapist motivated the person to be 
more active in their everyday lives and thus exhibit less negative symptoms.  Similarly it is 
possible that those with more insight felt that the relationship and therapy could be useful and 
therefore invested more into it. We also found associations between cannabis use and alliance 
from both clients’ and therapists’ perspectives possibly because consuming cannabis 
interferes with the development of a therapeutic bond between therapist and client and the 
client’s ability to focus on the therapeutic tasks. It is however noteworthy that none of the 
other substance misuse variables, including frequency of use were related to alliance. 
Barrowclough et al [12] did not find associations between substance misuse and alliance, but 
their sample comprised people using alcohol and a range of other substances with long 
histories of psychosis. To our knowledge no previous studies of alliance have focused 
specifically on therapy for cannabis use in the early stages of psychosis.  
Both the brief and longer-term therapy focused on developing a strong therapeutic alliance 
with clients and we did not predict that type of therapy would influence alliance scores. 
Although alliance scores were relatively high in both therapies and comparable to other 
studies of therapeutic alliance in psychosis [11, 12, 25], unexpectedly, clients-rated alliance 
was higher in the longer-term therapy. This finding could not be accounted for by other 
assessed differences in characteristics of participants in each group as the groups were 
comparable on other baseline measures and the timings of alliance ratings were similiar in 
both groups. It is possible that clients randomised to the longer-term intervention had greater 
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expectations for the therapy and therefore felt more positively towards their therapists. It is 
also possible that therapists were able to devote more time to building up alliance in the early 
sessions of the longer-term therapy compared to the briefer therapy where there may have 
been an increased pressure to focus on other therapeutic tasks.   
Although we identified possible predictors of alliance, a substantial degree of variance in the 
alliance was not explained by the variables assessed. The failure to identify strong predictors 
of alliance in psychosis in this study and in previous research is important as it highlights that 
it is possible for individuals with psychosis to develop strong relationships with therapists, 
even in the context of substance misuse. One study of CBT for psychosis showed that clients’ 
perceptions of therapists’ interpersonal qualities, such as empathy and trustworthiness may 
play a more important role than client characteristics and a need for further research to 
investigate therapist qualities as predictors of alliance [15].  
 
Although a number of studies have looked at cross-sectional associates of alliance in people 
with psychosis, this is one of the few studies to explore the role of alliance in this client group 
in predicting outcomes. Although client alliance was unrelated to substance misuse outcomes, 
early client alliance predicted total symptom scores at the 9-month and 18-month follow-ups 
and general functioning scores at all three follow-ups. A previous study of group CBT for 
early psychosis similarly reports associations between client alliance and clinical outcomes 
[11]. Although it might be argued that early improvements in symptoms and functioning may 
have confounded alliance ratings, evidence from well-designed studies in the general 
psychotherapy literature suggests that associations between early alliance and outcome is not 
accounted for by the effect of symptom change early in therapy [27]. The consistent 
associations between alliance and subsequent functioning (but not between baseline 
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functioning and alliance) are particularly interesting and suggest that positive therapeutic 
relationships may help patients improve relationships and functioning outside of therapy. 
 
Consistent with other research, clients’ assessment of alliance was a better predictor of 
outcomes than therapists’ assessments [11]. However, in line with these studies, therapists’ 
ratings of alliance were associated with clients’ attendance and completion of therapy, 
suggesting that therapists perceived that they had developed a better relationship with those 
who were more likely to attend.   
 
Results from studies investigating clients’ and therapists’ agreement about the quality of the 
therapeutic alliance have been mixed, with some reporting a significant association between 
their ratings [11, 16, 28] and others not [12, 29]. Tyron et al [30] report a meta-analysis of the 
association between client and therapist alliance across a range of different client groups and 
identify a moderate relationship between the two. We found reasonably high concordant rates 
between client and therapist ratings of alliance in this study which was greater than those 
reported in previous psychosis studies. It could be argued that the therapist and clients in this 
study were particularly open about their perceptions of the therapeutic relationship. However, 
it is also possible that the finding is influenced by missing data, with therapists and clients 
who had similar perceptions of alliance (and arguably better relationships) being more likely 
to complete alliance measures. Although we do not have the data to test this hypothesis, we 
did find that clients with completed alliance measures had significantly higher alliance scores 




A number of limitations of this study need to be taken into account. Although in the range of 
other alliance studies [12, 23, 24, 29], our sample was relatively small resulting in the 
possibility of Type II errors. It is noteworthy that some associations, for example, 
associations between client alliance and number of sessions attended, may have reached 
significance in larger samples. Conversely, it could be argued that the large number of 
analyses might have resulted in Type I errors. Readers should therefore be guided by our 
effect sizes in interpreting the meaning of findings.  The generalizability of our findings may 
be questioned.  All patients were participating in a RCT of MICBT thus limiting 
generalizability to naturalistic treatment settings in particular. A related issue was that not all 
potential participants completed the alliance assessment and clients with missing data 
differed from those with complete data. Missing data is a significant problem in alliance 
studies. In preparation for future trials, further work should ascertain the reasons for both 
therapist and client reluctance to complete alliance data and attempts should be made to 
overcome identified barriers. Further research would also benefit from measuring a wider 
range of experiences of the therapeutic relationships, for example, including those clients 
who did not complete therapy and may potentially experience the therapeutic relationship as 
less positive. An additional problem with our study is that we only report alliance ratings at 
one-point in time. It is known that therapeutic alliance can change over time [11, 31]. 
Previous studies measuring alliance over time have suggested that both fluctuations in 
alliance are themselves predictive of outcomes and that good therapeutic alliances are 
especially important at specific moments in therapy, namely when more difficult 
psychological work is done [11, 31].  
Limitations withstanding, our findings highlight a number of clinical implications. First, 
given the role of negative symptoms, poor insight and amount of cannabis use in predicting 
earlier alliance, therapists may need to spend more time engaging clients with these 
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presentations in the therapy in order establish stronger therapeutic bonds.  Second, therapists 
may need to ensure that problems in these domains are addressed early on in therapy. For 
example, behavioural activation may be a useful strategy to help clients with negative 
symptoms develop levels of activity, whereas psychoeducation and exploring models of 
psychosis early on in therapy may benefit those with poor insight. Tackling cannabis use 
early on with motivational interviewing strategies may be particularly important for heavy 
users.  Third, given the role of early client alliance in therapy outcomes, regularly assessing 
client alliance and providing additional supervision and support to therapists with clients with 
lower alliance scores to help therapists maximise therapeutic bonds and engagement may 
improve outcomes.  
 
 
5. CONCLUSION  
To our knowledge this is the first study to examine therapeutic alliance in a substance 
misusing group in the early stages of psychosis. Our findings add to the growing alliance and 
psychosis literature by demonstrating that it is possible for individuals with psychosis to 
develop strong relationships with their therapists even in the context of substance misuse and 
that those who do form better alliances gain greater benefits from therapy, at least in terms of 
improvements in functioning. Alliance is an important construct to measure in RCTs of 
psychological treatments for psychosis and future studies should focus on increasing therapist 






























Table 1: Sample characteristics for trial participants at baseline with WAI data  
N = 52  
 
Age in years, mean (SD) 23.76 (4.87) 
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Gender: male, n (%) 47 (90.4) 
Living arrangements, n (%)   
     Alone/ house-share/ hostel 19 (36.5) 
     With partner or family 33 (63.5) 
Ethnicity, n (%)   
    White 49 (94.2) 
    Black and Minority Ethnic 3 (5.8) 
Attended higher education, n (%) 27 (51.9) 
Employment, n (%)   
    Unemployed/ retired 42 (80.8) 
    Employed/ self-employed 3 (5.8) 
    Student 7 (13.5) 
History of psychosis (months), median 
(range) 
12,41  (1.35 – 
55.71) 
Duration of Untreated Psychosis, n (%)   
< 4 months 15 (28.8) 
>4 months 32 (61.5) 
Baseline Diagnosis (SCID-I)   
Schizophrenia 26 50.0 
Schizophreniform 3 5.8 
Schizoaffective 7 13.5 
Delusional Disorder 6 11.5 
Substance induced psychosis 1 1.9 
Psychotic Disorder not otherwise specified 9 17.3 
PANSS, mean (SD),    
     Positive 14.77 (4.01) 
     Negative 13.83 (4.63) 
     General 





Global functioning (GAF), mean (SD) 36.87  (8.52) 
Insight (BIS), mean (SD)            12.45    (3.04) 
Substance use disorder (SCID-I)¸ n (%)   
   Cannabis abuse                                                                    8 (15.4) 
   Cannabis dependence                                                   44 (84.6) 
History of cannabis use (years), mean (SD)            9.91 (4.78) 
Number of days abstinent from cannabis in     
preceding 30 day period, median (range)               
           12           (0-30) 
Number of days abstinent from all                                                              
substances in preceding 30 day period, 
median (range)                                                       
7 (0-30)
Average amount of cannabis per 
cannabis using day in preceding 30 days 
(grams), median (range) 
1.33 (.04- 7.3) 
Client alliance (WAI), mean (SD), 61.97 (9.25) 
Therapist alliance (WAI), mean (SD), 59.33 (10.17) 








Table 2: Correlations between WAI scores and baseline measures  
 WAI-client N = 35 WAI-therapist N = 52 
 r P R P 
PANSS positive  -.22 .216 -.12 .389 
PANSS negative  -.41 .013 -.25 .070 













.29 .088 .05 .724 
Insight (BIS) .41 .015 -.14 .320 




days 1  
.37 .027 .18 .194 
Number of days 
abstinent from 
all substances in 
preceding 30 
days 1 
.30 .081 .08 .592 
Average amount 
of cannabis per 
cannabis using 
day in preceding 
30 days (grams) 
1 
-.48 .005 -.31 .033 
 







Table 3: Regression models for client alliance, symptoms and functioning at all time points 
PANSS total 
4.5 months 
Adjusted R2 = .47, F = 10.45, df = 2, 24, p = 001 







.473 2.882 .008 .147 - .891 
Client alliance -.334 -2.034 .053 -1.074 - .008 
PANSS total  
9 months 
Adjusted R2 = .42, F = 10.49, df = 2, 24, p = .001 





.058 .326 .747 -.324 - .446 
Client alliance 
 
-.65 -3.631 .001 -1.623 - -.447 
PANSS total  
18 months 
Adjusted R2 = .46, F = 11.58, df = 2, 23, p < .001 
 Beta t P 95% 
confidence 
interval 
PANSS baseline  .398 2.328 .029 .044 - .753 
Client alliance  -.417 -2.435 .029 -1.118 - -.091 
GAF total  
4.5 months  
Adjusted R2 = .19, F = 4.13, df = 2, 24, p = .029 





.240 1.351 .189 -.177 - .848 
Client alliance 
 
.415 2.334 .028 .049 - .805 
GAF total 
9 months 
Adjusted R2 = .27, F = 5.71, df = 2, 24, p = .009 





.107 .557 .583 -.475 – .827 
Client alliance 
 
.509 2.658 .014 .157 – 1.246 
GAF total  
18 months  
Adjusted R2 = .57, F = 17.54, df = 2, 23, p = <.001 
 Beta t P 95% 
confidence 
interval  
GAF baseline  .515 3.521 .002 .463 – 1.781 
Client alliance  .398 2.719 .012 .170 – 1.248 
 
 




 WAI-client  WAI-therapist  




cannabis at 4.5 
months  
 




cannabis at 9 
months  
 




cannabis at 18 
months  
-.02 .907 .20 .234 
Percentage of 
reduction in 
days used all 
substances at 
4.5. months 
.19 .298 .26 .081 
Percentage of 
reduction in 
days used all 
substances at 9 
months 
-.06 .759 .21 .194 
Percentage of 
reduction in 
days used all 
substances at 18 
months 
-.12 .528 .16 .307 
 
Spearman rho reported 
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